Evidence map›Paper›PMID 33400739›Full record

ArticleOncotarget2020

Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study.

Pascale Tomasini, Fabrice Barlesi, Sophie Gilles, Isabelle Nanni-Metellus, Riccardo Soffietti, Emilie Denicolai, Eric Pellegrino, Emilie Bialecki, L'Houcine Ouafik, Philippe Metellus

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Pascale TomasiniAix Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & Therapeutic Innovations Department, Marseille, France.
Fabrice BarlesiAix Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology & Therapeutic Innovations Department, Marseille, France.
Sophie GillesAix Marseille University, Assistance Publique Hôpitaux de Marseille, CHU Nord, Service de Transfert d'Oncologie Biologique, Marseille, France.
Isabelle Nanni-MetellusAix Marseille University, Assistance Publique Hôpitaux de Marseille, CHU Nord, Service de Transfert d'Oncologie Biologique, Marseille, France.
Riccardo SoffiettiDepartment of Neuro Oncology, University and City of Health and Science Hospital, Turin, Italy.
Emilie DenicolaiPredictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR1068, CNRS UMR7258, Aix-Marseille Université UM105, Marseille, France.
Eric PellegrinoAix Marseille University, Assistance Publique Hôpitaux de Marseille, CHU Nord, Service de Transfert d'Oncologie Biologique, Marseille, France.
Emilie BialeckiRamsay Santé, Hôpital Privé Clairval, Département de Neurochirurgie, Marseille, France.
L'Houcine OuafikAix Marseille University, Assistance Publique Hôpitaux de Marseille, CHU Nord, Service de Transfert d'Oncologie Biologique, Marseille, France.
Philippe MetellusRamsay Santé, Hôpital Privé Clairval, Département de Neurochirurgie, Marseille, France.
Aix-Marseille Université · FRCentre National de la Recherche Scientifique · FRInserm · FRAssistance Publique Hôpitaux de Marseille · FRCentre de Recherche en Cancérologie de Marseille · FRHôpital privé Clairval · FRPiedmont Reference Center for Epidemiology and Cancer Prevention · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer brain metastases (BMs) are frequent and associated with poor prognosis despite a better knowledge of lung cancer biology and the development of targeted therapies. The inconstant intracranial response to systemic treatments is partially due to tumor heterogeneity between the primary lung tumor (PLT) and BMs. There is therefore a need for a better understanding of lung cancer BMs biology to improve treatment strategies for these patients. We conducted a study of whole exome sequencing of paired BM and PLT samples. The number of somatic variants and chromosomal alterations was higher in BM samples. We identified recurrent mutations in BMs not found in PLT. Phylogenic trees and lollipop plots were designed to describe their functional impact. Among the 13 genes mutated in ≥ 1 BM, 7 were previously described to be associated with invasion process, including 3 with recurrent mutations in functional domains which may be future targets for therapy. We provide with some insights about the mechanisms leading to BMs. We found recurrent mutations in BM samples in 13 genes. Among these genes, 7 were previously described to be associated with cancer and 3 of them (

Indexed as

brain metastasiscomparisonlung cancermutationswhole exome sequencing

Identifiers

PMID33400739
PMCPMC7747858
OpenAlexW3111098865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.